{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:46:52Z","timestamp":1790758012177,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:00:00Z","timestamp":1554336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:00:00Z","timestamp":1554336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1007\/s40262-019-00747-3","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T07:31:23Z","timestamp":1554363083000},"page":"827-833","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Levothyrox\u00ae New and Old Formulations: Are they Switchable for Millions of Patients?"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3916-577X","authenticated-orcid":false,"given":"Didier","family":"Concordet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4385-7894","authenticated-orcid":false,"given":"Peggy","family":"Gandia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6341-6001","authenticated-orcid":false,"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7661-4311","authenticated-orcid":false,"given":"Alain","family":"Bousquet-M\u00e9lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6629-1088","authenticated-orcid":false,"given":"Aude","family":"Ferran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8846-8892","authenticated-orcid":false,"given":"Pierre-Louis","family":"Toutain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,4]]},"reference":[{"key":"747_CR1","unstructured":"Levothyrox Enqu\u00eate officielle (2eme pr\u00e9sentation) Comit\u00e9 technique de pharmacovigilance le 30 javier; 2018. https:\/\/ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/7181268ac5a247ed769ea6b961d21232.pdf. Accessed 14 Dec 2018."},{"key":"747_CR2","unstructured":"Anonymous. Merck receives recommendation for approval in 21 EU countries for the new formulation of Euthyrox\u00ae. https:\/\/www.merckgroup.com\/en\/news\/euthyrox-approval-eu-26-07-2018.html. Accessed 16 Aug 2018."},{"key":"747_CR3","unstructured":"L\u2019ANSM publie les r\u00e9sultats des enqu\u00eates nationales de pharmacovigilance sur les sp\u00e9cialit\u00e9s \u00e0 base de l\u00e9vothyroxine. Communiqu\u00e9. ANSM. https:\/\/ansm.sante.fr\/S-informer\/Communiques-Communiques-Points-presse\/L-ANSM-publie-les-resultats-des-enquetes-nationales-de-pharmacovigilance-sur-les-specialites-a-base-de-levothyroxine-Communique. Accessed 17 Aug 2018."},{"key":"747_CR4","unstructured":"Anonymous. Levothyrox:changement de formule et de couleurs des boites des boites et des blisters. ANSM; 2017. https:\/\/ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Levothyrox-levothyroxine-changement-de-formule-et-de-couleur-des-boites-Point-d-Information-actualise. Accessed 17 Aug 2018."},{"key":"747_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/03007995.2016.1246434","volume":"33","author":"U Gottwald-Hostalek","year":"2017","unstructured":"Gottwald-Hostalek U, Uhl W, Wolna P, Kahaly GJ. New levothyroxine formulation meeting 95\u2013105% specification over the whole shelf-life: results from two pharmacokinetic trials. Curr Med Res Opin. 2017;33:169\u201374.","journal-title":"Curr Med Res Opin"},{"key":"747_CR6","unstructured":"Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence (EMA, London, 2010). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf. Accessed 16 Feb 2019."},{"key":"747_CR7","unstructured":"Anonymous. Guidance for industry. Statistical approaches to establishing bioequivalence. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research; 2001. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070244.pdf. Accessed 16 Feb 2019."},{"key":"747_CR8","unstructured":"Anonymous. Overview of comments received on draft guideline on the investigation of bioequivalence. EMA\/CHMP\/EWP\/26817\/2010. 2010;248."},{"key":"747_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1742-7843.2009.00518.x","volume":"106","author":"JAG Morais","year":"2010","unstructured":"Morais JAG, do Lobato MR. The new European Medicines Agency guideline on the investigation of bioequivalence. Basic Clin Pharmacol Toxicol. 2010;106:221\u20135.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"747_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0928-0987(97)10021-5","volume":"6","author":"L Endrenyi","year":"1998","unstructured":"Endrenyi L, Midha KK. Individual bioequivalence: has its time come? Eur J Pharm Sci. 1998;6:271\u20138.","journal-title":"Eur J Pharm Sci"},{"key":"747_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2165\/00003088-200140100-00001","volume":"40","author":"ML Chen","year":"2001","unstructured":"Chen ML, Lesko LJ. Individual bioequivalence revisited. Clin Pharmacokinet. 2001;40:701\u20136.","journal-title":"Clin Pharmacokinet"},{"key":"747_CR12","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1002\/1097-0258(20001030)19:20<2821::AID-SIM548>3.0.CO;2-L","volume":"19","author":"ML Chen","year":"2000","unstructured":"Chen ML, Patnaik R, Hauck WW, Schuirmann DJ, Hyslop T, Williams R. An individual bioequivalence criterion: regulatory considerations. Stat Med. 2000;19:2821\u201342.","journal-title":"Stat Med"},{"key":"747_CR13","doi-asserted-by":"publisher","first-page":"E42","DOI":"10.1208\/aapsj070105","volume":"7","author":"VA Blakesley","year":"2005","unstructured":"Blakesley VA. Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate. AAPS J. 2005;7:E42\u20136.","journal-title":"AAPS J"},{"key":"747_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF01062202","volume":"18","author":"S Anderson","year":"1990","unstructured":"Anderson S, Hauck WW. Consideration of individual bioequivalence. J Pharmacokinet Biopharm. 1990;18:259\u201373.","journal-title":"J Pharmacokinet Biopharm"},{"key":"747_CR15","volume-title":"Design and analysis of bioavailability and bioequivalence studies","author":"S-C Chow","year":"2009","unstructured":"Chow S-C, Liu J. Design and analysis of bioavailability and bioequivalence studies. 3rd ed. Boca Raton: CRC Press; 2009.","edition":"3"},{"key":"747_CR16","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1002\/1097-0258(20001030)19:20<2721::AID-SIM541>3.0.CO;2-8","volume":"19","author":"AL Gould","year":"2000","unstructured":"Gould AL. A practical approach for evaluating population and individual bioequivalence. Stat Med. 2000;19:2721\u201340.","journal-title":"Stat Med"},{"key":"747_CR17","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/1097-0258(20001030)19:20<2719::AID-SIM540>3.0.CO;2-P","volume":"19","author":"SC Chow","year":"2000","unstructured":"Chow SC, Liu JP. Preface. Bioequivalence measures. Stat Med. 2000;19:2719.","journal-title":"Stat Med"},{"key":"747_CR18","unstructured":"Rapports\/Synth\u00e8ses, M\u00e9dicaments, ANSM. Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. https:\/\/ansm.sante.fr\/Mediatheque\/Publications\/Rapports-Syntheses-Medicaments#folder_110079. Accessed 4 Sep 2018."},{"key":"747_CR19","first-page":"375","volume":"17","author":"WW Hauck","year":"2000","unstructured":"Hauck WW, Hyslop T, Chen ML, Patnaik R, Williams RL. Subject-by-formulation interaction in bioequivalence: conceptual and statistical issues. FDA Population\/Individual Bioequivalence Working Group. Food Drug Admin Pharm Res. 2000;17:375\u201380.","journal-title":"Food Drug Admin Pharm Res"},{"issue":"10","key":"747_CR20","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/j.xphs.2018.06.013","volume":"107","author":"R Cristofoletti","year":"2018","unstructured":"Cristofoletti R, Rowland M, Lesko LJ, Blume H, Rostami-Hodjegan A, Dressman JB. Past, present, and future of bioequivalence: improving assessment and extrapolation of therapeutic equivalence for oral drug products. J Pharm Sci. 2018;107(10):2519\u201330.","journal-title":"J Pharm Sci"},{"key":"747_CR21","doi-asserted-by":"publisher","first-page":"844","DOI":"10.18433\/J36P5M","volume":"18","author":"C Seng Yue","year":"2015","unstructured":"Seng Yue C, Benvenga S, Scarsi C, Loprete L, Ducharme MP. When bioequivalence in healthy volunteers may not translate to bioequivalence in patients: differential effects of increased gastric pH on the pharmacokinetics of levothyroxine capsules and tablets. J Pharm Pharm Sci. 2015;18:844\u201355.","journal-title":"J Pharm Pharm Sci"},{"key":"747_CR22","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.1210\/jc.2014-2684","volume":"99","author":"R Vita","year":"2014","unstructured":"Vita R, Saraceno G, Trimarchi F, Benvenga S. Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J Clin Endocrinol Metab. 2014;99:4481\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"747_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12020-018-1574-8","volume":"61","author":"I Laurent","year":"2018","unstructured":"Laurent I, Tang S, Ast\u00e8re M, Wang KR, Deng S, Xiao L, et al. Liquid l-thyroxine versus tablet l-thyroxine in patients on l-thyroxine replacement or suppressive therapy: a meta-analysis. Endocrine. 2018;61:28\u201335.","journal-title":"Endocrine"},{"key":"747_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","volume":"58","author":"M Lindenberg","year":"2004","unstructured":"Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model List of Essential Medicines according to the Biopharmaceutics Classification System. Eur J Pharm Biopharm. 2004;58:265\u201378.","journal-title":"Eur J Pharm Biopharm"},{"key":"747_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0928-0987(99)00076-7","volume":"9","author":"HH Blume","year":"1999","unstructured":"Blume HH, Schug BS. The biopharmaceutics classification system (BCS): class III drugs\u2014better candidates for BA\/BE waiver? Eur J Pharm Sci. 1999;9:117\u201321.","journal-title":"Eur J Pharm Sci"},{"key":"747_CR26","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1208\/s12248-013-9509-z","volume":"15","author":"M-L Chen","year":"2013","unstructured":"Chen M-L, Sadrieh N, Yu L. Impact of osmotically active excipients on bioavailability and bioequivalence of BCS class III drugs. AAPS J. 2013;15:1043\u201350.","journal-title":"AAPS J"},{"key":"747_CR27","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/jps.2600841205","volume":"84","author":"DA Adkin","year":"1995","unstructured":"Adkin DA, Davis SS, Sparrow RA, Huckle PD, Wilding IR. The effect of mannitol on the oral bioavailability of cimetidine. J Pharm Sci. 1995;84:1405\u20139.","journal-title":"J Pharm Sci"},{"key":"747_CR28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1023\/A:1016256619309","volume":"12","author":"DA Adkin","year":"1995","unstructured":"Adkin DA, Davis SS, Sparrow RA, Huckle PD, Phillips AJ, Wilding IR. The effect of different concentrations of mannitol in solution on small intestinal transit: implications for drug absorption. Pharm Res. 1995;12:393\u20136.","journal-title":"Pharm Res"},{"key":"747_CR29","unstructured":"Anonymous. Rapport d\u2019analyse de conformit\u00e9 de la nouvelle formulation du Levothyrox effectu\u00e9 par les laboratoires de l\u2019ANSM. https:\/\/ansm.sante.fr\/S-informer\/Communiques-Communiques-Points-presse\/L-ANSM-a-realise-dans-ses-laboratoires-plusieurs-controles-sur-la-composition-de-Levothyrox-nouvelle-formule-qui-ont-confirme-sa-bonne-qualite-Communique. Accessed 17 Aug 2018."},{"key":"747_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejps.2014.09.004","volume":"65","author":"A Garc\u00eda-Arieta","year":"2014","unstructured":"Garc\u00eda-Arieta A. Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: impact on bioequivalence. Eur J Pharm Sci. 2014;65:89\u201397.","journal-title":"Eur J Pharm Sci"},{"key":"747_CR31","unstructured":"US FDA. Draft guidance on methylphenidate hydrochloride. 2018. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM320007.pdf. Accessed 17 Aug 2018."},{"key":"747_CR32","doi-asserted-by":"publisher","first-page":"b5613","DOI":"10.1136\/bmj.b5613","volume":"339","author":"K Faasse","year":"2009","unstructured":"Faasse K, Cundy T, Petrie KJ. Medicine and the media. Thyroxine: anatomy of a health scare. BMJ. 2009;339:b5613.","journal-title":"BMJ"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00747-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-019-00747-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00747-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T19:55:00Z","timestamp":1606247700000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-019-00747-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,4]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"alternative-id":["747"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00747-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,4]]},"assertion":[{"value":"4 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Didier Concordet, Peggy Gandia, Jean L. Montastruc, Alain Bousquet-M\u00e9lou, Peter Lees, Aude Ferran, and Pierre L. Toutain declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"PG retrieved and validated raw data, AF validated raw data, DC performed the statistical analysis, and PLT and DC drafted the articles. All co-authors critically reviewed several drafts of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}